Cantor Fitzgerald raises target for Amgen stock from USD 400 to USD 440
Published on 10/09/2026 at 16:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Cantor Fitzgerald raised its Amgen price target from USD 400.00 to USD 440.00 on October 8, 2026 while keeping a Neutral rating.
- Amgen's second-quarter 2026 revenue reached USD 10.05 billion, 9.50 percent above the year-earlier period.
- The Lang & Schwarz price was EUR 368.18 on October 9, 2026, up 2.25 percent versus the EUR 360.08 prior close.
- OASIZ 303 is expected to complete in the fourth quarter of 2026, while third-quarter results are scheduled for November 3, 2026.
Cantor Fitzgerald raised its price target for Amgen stock from USD 400.00 to USD 440.00 on October 8, 2026, while maintaining a Neutral rating, according to Investing.com. The move places the analyst target above Amgen's euro reference price, but the rating keeps the assessment cautious.
Target rises as pipeline matters
Cantor Fitzgerald tied its October 8, 2026 view to continued commercial performance in the second half of 2026 and upcoming MariTide data expected in the first half of 2027, according to Investing.com. The same report said the firm was seeking further clarity on the Sjogren's profile and the second study of dazodalibep.
Amgen's second-quarter 2026 revenue was USD 10.05 billion, compared with a USD 9.43 billion consensus estimate, and revenue increased 9.50 percent from the same quarter a year earlier, according to MarketBeat. That comparison gives the target increase a commercial backdrop beyond the clinical pipeline.
Three dated signals for Amgen
On August 4, 2026, Amgen reported second-quarter revenue of USD 10.05 billion and year-over-year revenue growth of 9.50 percent, according to MarketBeat. On September 22, 2026, Amgen said its Phase 3 OASIZ 301 study reached its primary endpoint at Week 48, according to Amgen. On October 8, 2026, Cantor Fitzgerald lifted its target from USD 400.00 to USD 440.00, according to Investing.com.
What must Amgen prove next?
The next clinical test is OASIZ 303, which Amgen expects to complete in the fourth quarter of 2026. Reuters reported on September 22, 2026, that analysts viewed two positive late-stage studies as important for a potential FDA approval path. The report also noted that detailed OASIZ 301 data still had to be compared with competing development programs.
Upcoming dates and stock context
Amgen's next reporting date is November 3, 2026, for third-quarter 2026 results, according to TradingView. The company also expects OASIZ 303 completion in the fourth quarter of 2026, creating two separate dates for investors to track.
Amgen stock trades higher in euros
Amgen stock was trading at EUR 368.18 at Lang & Schwarz on October 9, 2026 at 4:31 p.m. CEST, up 2.25 percent versus the Lang & Schwarz prior close of EUR 360.08 on October 8, 2026. Amgen is listed on the Nasdaq under ticker AMGN, and its market capitalization was USD 222.6 billion as of October 9, 2026.
The further course of trading is shown by the continuously updated real-time quote of Amgen stock.
Amgen stock facts
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 9, 2026 at 4:31 p.m. CEST: EUR 368.18
- Change versus prior close: plus 2.25 percent
- Prior close Lang & Schwarz October 8, 2026: EUR 360.08
- Market capitalization: USD 222.6 billion as of October 9, 2026
- Sector / Industry: Health Care / Biotechnology
- Index membership: Dow Jones Industrial Average and Nasdaq-100
- Next earnings date: November 3, 2026
Market context: Market report S&P 500.
